Is Ozempic ruining your teeth? What to know about impact on dental health

Despite their widely touted benefits — primarily weight loss and diabetes control, among others — GLP-1 medications have also been linked to some unwelcome side effects. In addition to the main complaints of gastrointestinal issues, some lesser-known side effects have emerged, including mood changes, hair loss and “Ozempic face.” Now, there are rumblings on social […]
ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death

For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related cancer compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, according to a study scheduled to be presented at the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.
GLP-1 prescriptions for weight loss are shooting up, despite obstacles

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a new Fair Health report.
Veru’s obesity drug roughly as safe as Wegovy; Keros’ board fight

Plus, news about Advanz, Alvotech and GeNeuro: Veru’s obesity drug generally safe when added to Wegovy: In the Phase 2b QUALITY trial, patients who were given enobosarm, an oral androgen receptor modulator …
GLP-1 prescriptions for weight loss soar, despite obstacles

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, according to a new report.
Cysteine Deficiency Drives Weight Loss by Depleting CoA

This research paper explores the impact of amino acid restriction on weight loss, focusing on the unique effects of cysteine deficiency. The study demonstrates that cysteine restriction in mice, particularly those with compromised cysteine synthesis, leads to rapid and significant weight loss, primarily through fat reduction. This weight loss is linked to the activation of stress responses, reduced levels of key metabolites like CoA, and resulting metabolic inefficiency, […]
Blue Cross Blue Shield plans reverse course on GLP-1 coverage

Blue Cross plans are retreating from GLP-1 weight-loss drug coverage after spending hundreds of millions of dollars on the highly popular medications.
Author Correction: GLP-1-based therapies for diabetes, obesity and beyond

Nature Reviews Drug Discovery, Published online: 28 May 2025; doi:10.1038/s41573-025-01231-3 Author Correction: GLP-1-based therapies for diabetes, obesity and beyond
Weight-loss drugs may lower risk of obesity-related cancers

Popular GLP-1 weight-loss drugs like Ozempic and Zepbound can help reduce a woman’s risk for as many as 14 cancers associated with obesity, a new study says.
Weight-Loss Drugs May Lower Risk Of Obesity-Related Cancers

By Dennis Thompson HealthDay ReporterWEDNESDAY, May 28, 2025 (HealthDay News) — Popular GLP-1 weight loss drugs like Ozempic and Zepbound can help…